Roth Capital Partners Initiates Coverage on Mydecine

← Back to all news
June 22, 2021

Published at

Roth Capital Partners is initiating coverage of Mydecine with a Buy rating and $3/share price target. Mydecine is the first to treat PTSD and smoking cessation with the natural form of psilocybin (MYCO – 001).

To read full report, click here.